CN109219607A - 二肽基肽酶-iv 抑制剂的丁二酸盐的晶型 - Google Patents

二肽基肽酶-iv 抑制剂的丁二酸盐的晶型 Download PDF

Info

Publication number
CN109219607A
CN109219607A CN201780032328.3A CN201780032328A CN109219607A CN 109219607 A CN109219607 A CN 109219607A CN 201780032328 A CN201780032328 A CN 201780032328A CN 109219607 A CN109219607 A CN 109219607A
Authority
CN
China
Prior art keywords
crystal form
compound
succinate
methyl
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780032328.3A
Other languages
English (en)
Other versions
CN109219607B (zh
Inventor
舒楚天
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jilin Huisheng Biopharmaceutical Co ltd
Beijing Huizhiheng Biological Technology Co Ltd
Original Assignee
Xuanzhu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xuanzhu Pharma Co Ltd filed Critical Xuanzhu Pharma Co Ltd
Publication of CN109219607A publication Critical patent/CN109219607A/zh
Application granted granted Critical
Publication of CN109219607B publication Critical patent/CN109219607B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)

Abstract

本发明涉及二肽基肽酶‑IV抑制剂的丁二酸盐的晶型、其制备方法、药物组合物及应用。具体地涉及作为二肽基肽酶‑IV抑制剂的式(1)所示化合物(R)‑2‑((7‑(3‑氨基哌啶‑1‑基)‑3,5‑二甲基‑2‑氧代‑2,3‑二氢‑1H‑咪唑并(4,5‑b)吡啶‑1‑基)甲基)苯甲腈的丁二酸盐的晶型、其制备方法、药物组合物及应用。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN201780032328.3A 2016-06-08 2017-06-07 二肽基肽酶-iv抑制剂的丁二酸盐的晶型 Active CN109219607B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016104111267 2016-06-08
CN201610411126 2016-06-08
PCT/CN2017/087433 WO2017211293A1 (zh) 2016-06-08 2017-06-07 二肽基肽酶-iv抑制剂的丁二酸盐的晶型

Publications (2)

Publication Number Publication Date
CN109219607A true CN109219607A (zh) 2019-01-15
CN109219607B CN109219607B (zh) 2021-03-30

Family

ID=60578368

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780032328.3A Active CN109219607B (zh) 2016-06-08 2017-06-07 二肽基肽酶-iv抑制剂的丁二酸盐的晶型

Country Status (2)

Country Link
CN (1) CN109219607B (zh)
WO (1) WO2017211293A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102127072A (zh) * 2010-01-15 2011-07-20 山东轩竹医药科技有限公司 吡啶并环衍生物
WO2013046229A1 (en) * 2011-09-26 2013-04-04 Hetero Research Foundation Novel salts of alogliptin
CN102863440B (zh) * 2011-07-09 2015-05-27 山东轩竹医药科技有限公司 二肽基肽酶-iv抑制剂的盐的晶型

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102127072A (zh) * 2010-01-15 2011-07-20 山东轩竹医药科技有限公司 吡啶并环衍生物
WO2011085643A8 (zh) * 2010-01-15 2012-07-05 山东轩竹医药科技有限公司 吡啶并环衍生物
CN102863440B (zh) * 2011-07-09 2015-05-27 山东轩竹医药科技有限公司 二肽基肽酶-iv抑制剂的盐的晶型
WO2013046229A1 (en) * 2011-09-26 2013-04-04 Hetero Research Foundation Novel salts of alogliptin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHU，CHUTIAN 等: "《Discovery of Imigliptin，a Novel Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes》", 《ACS MEDICINAL CHEMISTRY LETTERS》 *

Also Published As

Publication number Publication date
WO2017211293A1 (zh) 2017-12-14
CN109219607B (zh) 2021-03-30

Similar Documents

Publication Publication Date Title
TWI322805B (zh)
US9518059B2 (en) Inhibitor crystalline form and preparation method and use thereof
US11168072B2 (en) Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof
WO2022122014A1 (zh) Lanifibranor的晶型及其制备方法和用途
CN103476742B (zh) 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物
EP3322704B1 (en) Crystalline form of n-[(3-amino-3-oxetanyl)methyl]-2-(2,3-dihydro-1,1-dioxido-1,4-benzothiazepin-4(5h)-yl)-6-methyl-4-quinazolinamine for the treatment of respiratory syncytial virus (rsv) infections
EP2809661A1 (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors
JP2022528747A (ja) Ｆａｋ阻害剤の塩及び結晶形態
US11299474B2 (en) Crystal form targeting CDK4/6 kinase inhibitor
CN103476743B (zh) 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物
US10793588B2 (en) Crystal form of sodium-glucose cotransporter 2 inhibitor
CN109219607A (zh) 二肽基肽酶-iv 抑制剂的丁二酸盐的晶型
CN113999211B (zh) 一类特异性抗前列腺癌活性的含1,2,3-三氮唑的吲唑骨架衍生物
CN101622257B (zh) N-{2-氟-5-[3-(噻吩-2-羰基)-吡唑并[1,5-a]嘧啶-7-基]-苯基}-N-甲基-乙酰胺的多晶型B
CN112574130B (zh) 一种法匹拉韦药物共晶及其制备方法和应用
CN108699094A (zh) 一种钠依赖性葡萄糖共转运蛋白抑制剂的胺溶剂合物及其制备方法和应用
CN113045554A (zh) 一种非索替尼晶型及其制备方法
CN108602817B (zh) 二肽基肽酶-iv抑制剂的苯甲酸盐的晶型
EP3395819B1 (en) Crystal form of substituted aminopyran derivative
US20200361919A1 (en) Deuterated indoleamine 2,3-dioxygenase inhibitor and application thereof
CN109369634B (zh) 具有抗肿瘤活性的2-甲氧基烟酰胺衍生物制备方法及用途
CN109384739B (zh) 一种可比司他新晶型及其制备方法
CN103360383B (zh) 鲁拉西酮盐酸盐的晶型b及其制备方法
US20240092768A1 (en) Crystal form of anti-influenza virus compound, preparation method for crystal form, and use of crystal form
CN113801068B (zh) 一种吉非替尼的有机酸盐

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20191025

Address after: Room 510, building 2, No. 88, Kechuang 6th Street, Beijing Economic and Technological Development Zone, Beijing 100176

Applicant after: Xuanzhu (Beijing) Pharmaceutical Technology Co.,Ltd.

Address before: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 2518

Applicant before: XUANZHU PHARMA Co.,Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20200924

Address after: 135000 No. 666, Kangmei Avenue, Meihekou City, Tonghua City, Jilin Province

Applicant after: Jilin Huisheng biopharmaceutical Co.,Ltd.

Applicant after: Beijing huizhiheng Biotechnology Co.,Ltd.

Address before: Room 510, building 2, No. 88, Kechuang 6th Street, Beijing Economic and Technological Development Zone, Beijing 100176

Applicant before: Xuanzhu (Beijing) Pharmaceutical Technology Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: 135007 No. 666, Kangmei Avenue, Meihekou City, Tonghua City, Jilin Province

Patentee after: Jilin Huisheng Biopharmaceutical Co.,Ltd.

Patentee after: Beijing huizhiheng Biotechnology Co.,Ltd.

Address before: NO.666 Kangmei Avenue, Meihekou City, Tonghua City, Jilin Province

Patentee before: Jilin Huisheng biopharmaceutical Co.,Ltd.

Patentee before: Beijing huizhiheng Biotechnology Co.,Ltd.

CP03 Change of name, title or address